Home » Stocks » PTE

PolarityTE, Inc. (PTE)

Stock Price: $1.43 USD -0.03 (-2.05%)
Updated Mar 3, 2021 10:30 AM EST - Market open
Market Cap 97.53M
Revenue (ttm) 8.00M
Net Income (ttm) -53.94M
Shares Out 38.76M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $1.43
Previous Close $1.46
Change ($) -0.03
Change (%) -2.05%
Day's Open 1.51
Day's Range 1.39 - 1.57
Day's Volume 2,295,778
52-Week Range 0.55 - 2.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H...

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Other stocks mentioned: RVNC, VIE
Business Wire - 3 weeks ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide thi...

Business Wire - 3 weeks ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/1...

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrol...

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors h...

InvestorPlace - 1 month ago

PolarityTE (PTE) stock is soaring higher on Friday as investors prepare for its participation in an upcoming event on Monday. The post PTE Stock Alert: 7 Things for Investors to Know About Pol...

Business Wire - 1 month ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H...

Business Wire - 2 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...

Business Wire - 3 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. ...

Business Wire - 3 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...

Seeking Alpha - 3 months ago

PolarityTE, Inc. (PTE) CEO David Seaburg On Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

PolarityTE, Inc.'s (PTE) CEO David Seaburg on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

  Shares of PolarityTE (NASDAQ:PTE) moved higher by 7.3% in pre-market trading after the company reported Q3 results.

Business Wire - 3 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the thir...

Business Wire - 4 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submi...

Business Wire - 4 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 a...

Business Wire - 5 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder...

Business Wire - 5 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the Nation...

Business Wire - 5 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlle...

Business Wire - 5 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M.

Business Wire - 5 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C.

Seeking Alpha - 6 months ago

PolarityTE, Inc. (PTE) CEO David Seaburg on Q2 2020 Results - Earnings Call Transcript

Business Wire - 6 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the seco...

Business Wire - 7 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors.

Business Wire - 7 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 ...

Business Wire - 7 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center random...

Business Wire - 7 months ago

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized co...

Zacks Investment Research - 8 months ago

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: AVGR, CSV, MOGO, TNK
Forbes - 9 months ago

It is possible that the markets have run too far making today ideal for taking a few short positions. According to our deep learning algorithms, these are the ones to go after.

Other stocks mentioned: BPT, DVN, HAL, LVS
Seeking Alpha - 9 months ago

PolarityTE's (PTE) CEO David Seaburg on Q1 2020 Results - Earnings Call Transcript

Benzinga - 9 months ago

Shares of PolarityTE (NASDAQ:PTE) were flat in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 10 months ago

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

Seeking Alpha - 11 months ago

PolarityTE, Inc.'s (PTE) Management on Q4 2019 Results - Earnings Call Transcript

Market Watch - 1 year ago

Shares of PolarityTE Inc. plummeted 46% in premarket trading Wednesday, putting them on track to open at a record low, after the regenerative tissue products and biomaterials company said it p...

Zacks Investment Research - 1 year ago

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND, PRTK, VKTX, XON, ZIOP
Seeking Alpha - 1 year ago

PolarityTE: Turning The Ship Around

Seeking Alpha - 1 year ago

PolarityTE, Inc. (PTE) Management on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

It was a busy few months for PolarityTE including a leadership change and short-term focus shift. Both are welcome, but there is a huge tail risk involved.

Seeking Alpha - 1 year ago

PolarityTE, Inc. (PTE) Management on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

SkinTE is a transformational alternative to STSGs (split-thickness skin grafts), the standard-of-care for severe burns and wounds.

Zacks Investment Research - 1 year ago

PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GuruFocus - 1 year ago

According to GuruFocus Insider Data, the recent CFO buys were: Freeport-McMoRan Inc, PolarityTE Inc. & Coeur Mining Inc.

Other stocks mentioned: CDE, FCX
Benzinga - 1 year ago

Polarityte Inc (NASDAQ: PTE) shares were seeing an upward bounce Monday in reaction to a clinical trial readout at the American Diabetes Association's 79th Scientific Sessions conference.

Seeking Alpha - 1 year ago

PolarityTE has developed a regenerative medical technology that is already showing outstanding results in the clinic.

About PTE

PolarityTE, a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the ini... [Read more...]

Industry
Biotechnology
IPO Date
Aug 13, 1999
CEO
Denver Lough
Employees
153
Stock Exchange
NASDAQ
Ticker Symbol
PTE
Full Company Profile

Financial Performance

In 2019, PolarityTE's revenue was $5.65 million, an increase of 261.61% compared to the previous year's $1.56 million. Losses were -$92.49 million, 41.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PolarityTE stock is "Buy." The 12-month stock price forecast is 3.00, which is an increase of 109.79% from the latest price.

Price Target
$3.00
(109.79% upside)
Analyst Consensus: Buy